As our institute (Sher-i-Kashmir Institute of Medical Sciences (SKIMS)) happens to be the only referral institute for leukemia patients including CML, the primary objective behind our work was to establish the real-time quantitative assay for BCR-ABL transcripts in order to help monitor the treatment of CML patients in our setting. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.